New drug shows promise for Hard-to-Treat lung cancer
NCT ID NCT03260491
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a drug called HER3-DXd in people with advanced non-small cell lung cancer that has spread or cannot be removed by surgery. The study includes patients with specific genetic changes (EGFR or KRAS mutations) whose cancer worsened after other treatments. The goal is to check safety and see if the drug shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HER3-DXd (patritumab deruxtecan)
What this could lead to
If successful, this could provide a new treatment option for patients with advanced lung cancer who have not responded to other therapies.
What could go wrong
This is an early-phase trial, so the drug may not prove effective or may cause unexpected side effects. Results may not apply to all lung cancer patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, 05505, South Korea
-
Chung Shan Medical University Hospital
Taichung, 40705, Taiwan
-
City of Hope
Duarte, California, 91010, United States
-
Clinica Universidad Navarra(Madrid)
Madrid, 28027, Spain
-
Clínica Universidad de Navarra (Pamplona)
Pamplona, 31008, Spain
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
Gabrail Cancer Center (GCC) - Canton Facility
Canton, Ohio, 44718-2566, United States
-
Henry Ford Hospital
Detroit, Michigan, 48202, United States
-
Hospital General Universitario Gregorio Maranon (HGUGM)
Madrid, 28007, Spain
-
Hospital Ramón y Cajal
Madrid, 28034, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Madrid Sanchinarro - Centro Integral Oncologico Clara Campal (CIOCC)
Madrid, 28050, Spain
-
Hospital Universitario Quirónsalud Madrid
Madrid, 28223, Spain
-
Hospital Universitario Vall d'Hebron
Barcelona, 08035, Spain
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Kindai University Hospital
Osaka, 5898511, Japan
-
Kurume University - Kurume University Hospital - Respiratory Diseases Center
Kurume-Shi, 830-0011, Japan
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States
-
NEXT Oncology - Hospital Quironsalud Barcelona
Barcelona, 08023, Spain
-
NYU Langone Health - NYU Medical Oncology Associates
New York, New York, 10016-4744, United States
-
National Cancer Center Hospital East (NCCHE) - Kashiwa Campus
Kashiwa-Shi, 277-8577, Japan
-
National Cheng Kung University Hospital
Tainan, 00704, Taiwan
-
National Taiwan University Hospital
Taipei, 00100, Taiwan
-
Netherlands Cancer Institute
Amsterdam, 1066 CX, Netherlands
-
Northwest Medical Specialties
Tacoma, Washington, 98405, United States
-
Oncology Consultants P.A.
Houston, Texas, 77030, United States
-
Pacific Shores Medical Group
Long Beach, California, 90813, United States
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Sarah Cannon Research Institute/Tennesse Oncology
Nashville, Tennessee, 37203, United States
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Shizuoka Cancer Center
Shizuoka, 4118777, Japan
-
The Cancer Institute Hospital of Japanese Foundation for Cancer Research (JFCR)
Tokyo, 1358550, Japan
-
University of California San Diego
La Jolla, California, 92093, United States
-
University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center (University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, 15232-1301, United States
-
Winship Cancer Institute of Emory University
Atlanta, Georgia, 30322, United States